Rate Video

EHA 2015 | Future perspectives in the treatment of acute lymphoblastic leukemia

Dieter Hoelzer • 12 Jun 2015

Acute Lymphoblastic Leukemia

At the 20th Congress of the European Hematology Association (EHA), Dieter Hoelzer, MD, PhD, of Goethe University Hospital, Frankfurt, Germany, discusses the possibilities of immunotherapy for the treatment of patients with acute lymphoblastic leukemia.

Exploring the potential of T-cell therapy for acute lymphoblastic leukemia

Dieter Hoelzer • 12 Jun 2015

The evolving landscape of ALL therapy and the impact of MRD

Dieter Hoelzer et al.

CAR T-cells and BiTEs for hematological malignancies

Efficacy and safety of CD19-targeted CAR T-cells for relapsed/refractory ALL

Dieter Hoelzer • 12 Jun 2015

Related Videos

Current standard of care in BPDCN

Uwe Platzbecker • 21 Jun 2022

Dose-adjusted EPOCH plus inotuzumab ozogamicin for B-ALL

Ryan Cassaday • 20 Jun 2022

Delphinus: daratumumab in R/R T-ALL & T-LBL

Ajay Vora • 15 Jun 2022

Managing patients with T-ALL who relapse or are refractory to first-line treatment

Ajay Vora • 15 Jun 2022